Newsroom | 48752 results

NATICK, Mass. & LONDON--(BUSINESS WIRE)--Aleta Biotherapeutics, a clinical stage immuno-oncology company developing CAR T-cell engager biologics that enable CAR T-cell cancer therapies to work more effectively, and Cancer Research UK’s Centre for Drug Development, today announced promising results from the phase I/II clinical trial of ALETA-001 in patients who have received anti-CD19 CAR T-cell therapy for the treatment of B-cell malignancies. The multi-centre, open-label clinical trial (NCT060...

MENLO PARK, Calif.--(BUSINESS WIRE)--Orca Bio presents positive new data from its pipeline of allogeneic T-cell immunotherapies at the 67th ASH Annual Meeting....

SOMERVILLE, Mass.--(BUSINESS WIRE)--Cellarity presented new preclinical data on investigational programs for sickle cell disease and myelofibrosis during the ASH Annual Meeting....

LONDON & CHICAGO--(BUSINESS WIRE)--Anova Enterprises, Inc. (Anova), a technology-enabled CRO dedicated to improving the conduct of clinical trials, today announced the completion of enrollment of 550+ patients at 50+ sites for a single study in just six months, using it’s proprietary AnovaOS™ Platform. The program provided cancer doctors and patients with a promising treatment that was otherwise unavailable. The sponsor was provided with safety and efficacy data to support its drug development...

EVANSTON, Ill.--(BUSINESS WIRE)--Flashpoint Therapeutics, a biotechnology company pioneering a new class of structural nanomedicines, today congratulates its scientific co-founder, Professor Chad A. Mirkin, on being awarded the Harvey Prize in Science and Technology. The prestigious international prize, awarded by the Technion, Israel Institute of Technology in Haifa, recognizes Professor Mirkin for groundbreaking discoveries that have fundamentally reshaped the fields of nanoscience and nanote...

LYON, France--(BUSINESS WIRE)--Regulatory News: MaaT Pharma (EURONEXT : MAAT - la « Société »), société de biotechnologies en stade clinique avancé, leader dans le développement de Microbiome Ecosystem TherapiesTM (MET)1 visant à améliorer la survie des patients atteints de cancers grâce à la modulation du système immunitaire, annonce aujourd’hui que le docteur Florent Malard, PhD et professeur d’hématologie à l’Hôpital Saint-Antoine et à Sorbonne Université, et investigateur principal de l’ess...

LYON, France--(BUSINESS WIRE)--MaaT Pharma Presents Pivotal ARES Phase 3 Results for MaaT013 in Acute GvHD at ASH 2025 Annual Congress and Announces 54% 1-Year Overall Survival....

NEWTON, Mass.--(BUSINESS WIRE)--Abcuro, Inc., a late-stage clinical biotechnology company developing potentially first-in-class immunotherapies designed to benefit people living with debilitating and progressive rare autoimmune diseases and for other indications where certain cytotoxic T cells are pathogenic, today presented interim data from the ongoing Phase 1/2 clinical trial evaluating ulviprubart (ABC008) in patients with T cell large granular lymphocytic leukemia (T-LGLL) with anemia and/...

BARCELONA, Spain--(BUSINESS WIRE)--REVEAL GENOMICS, S.L., a Barcelona-based biotechnology company focused on advancing precision oncology through biomarker innovation, announced today the presentation of seven studies at the upcoming San Antonio Breast Cancer Symposium (SABCS) 2025, held December 9–12 in San Antonio, Texas. These abstracts showcase the growing clinical utility and innovation of the company’s proprietary RNA platform and underscore REVEAL GENOMICS’ commitment to improving outcom...

SOMERVILLE, Mass.--(BUSINESS WIRE)--Genetix Biotherapeutics Inc. today announced real-world data from the commercial implementation of ZYNTEGLO™ and LYFGENIA™, first-in-class ex vivo gene addition therapies for the treatment of beta-thalassemia and sickle cell disease. With over 250 patients treated with these therapies, inclusive of clinical trials and commercial treatments, and long-term follow-up data beyond 10 years, Genetix has the most robust long-term dataset in ex vivo gene therapy for...